1. Marimastat (BB2516): Current status of development
2. Yocum, S. A.; Lopresti-Morrow, L. L.; Reeves, L. M.; Mitchell, P. G. In Inhibition of Matrix Metalloproteinases: Therapeutic Applications; Greenwald, R. A., Zucker, S., Golub, L. M., Eds.; The New York Academy of Sciences: NY, 1999; pp 583–586.
3. The hypothesis that sparing MMP-1 is necessary and sufficient to prevent the musculoskeletal stiffening has been called into question in view of recent clinical results where it is observed that certain inhibitors that inhibit MMP-1 nevertheless do not appear to show the side effect. See Shaw, T.; Nixon, J. S.; Bottomley, K. M. Exp. Opin. Invest. Drugs 2000, 9, 1469.
4. Shalinsky, D. R.; Brekken, J.; Zou, H.; McDermott, C. D.; Forsyth, P.; Edwards, D.; Margosiak, S.; Bender, S.; Truitt, G.; Wood, A.; Varki, N. M.; Appelt, K. In Inhibition of Matrix Metalloproteinases: Therapeutic Applications; Greenwald, R. A., Zucker, S., Golub, L. M., Eds.; The New York Academy of Sciences: NY, 1999; pp 236–270.